TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02910583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib administered orally once daily (three 140 mg capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibrutinib
Description: ibrutinib administered orally once daily (three 140 mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib administered orally once daily (three 140 mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib administered orally once daily (three 140 mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
Study: NCT03656900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological assessment
Description: Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological assessment
Description: Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
Study: NCT00409708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavior Therapy
Study: NCT06396845

Intervention type: PROCEDURE
Intervention: robotic surgery
Description: robotic surgery

Intervention type: PROCEDURE
Intervention: robotic surgery
Description: robotic surgery

Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: laparoscopic surgery

Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: laparoscopic surgery
Study: NCT03016897

Intervention type: OTHER
Intervention: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Description: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter

Intervention type: OTHER
Intervention: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Description: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter

Intervention type: OTHER
Intervention: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Description: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Study: NCT05452629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness induction (MI)
Description: In the MI condition, participants were guided to focus on present experiences regarding the thoughts, emotions and sensations through the three classic mindfulness exercises (i.e., focused breathing, meditation, and body scanning). The duration of MI was 30-minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation (RI)
Description: In the RI condition, participants were guided to relax each muscle group following the audio for 30-minutes.
Study: NCT04463043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SelfBACK app
Description: The selfBACK is an evidence-based and data-driven decision support system (DSS) to support self-management of low back and neck pain delivered via a smartphone app. The selfBACK app provides individually tailored self-management plans to participants on a weekly basis by matching the participant's health information with targeted educational messages, physical activity advices and exercise recommendations via the DSS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-Help webpage
Description: The e-Help is an evidence-based web-based resource to support self-management of low back and neck pain. The e-Help webpage provides evidence-based self-management content equivalent to the selfBACK including educational messages, physical activity and exercise recommendations. Instructions on how to compose exercise programs will be given to participants, however no tailored self-management support will be offered in this solution.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care refers to seeking care or receiving treatments or help as usual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care refers to seeking care or receiving treatments or help as usual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care refers to seeking care or receiving treatments or help as usual.
Study: NCT03717545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: second allogeneic stem cell transplantation
Description: 1. Change another donor~2. conditioning regimen: FLU/CY/anti-CD25 moAb
Study: NCT02334943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test
Study: NCT02243072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit Families plus Standard Medical Care
Description: Adolescents will receive the Fit Families plus Standard Medical Care which consists of twice weekly home-based, family psychotherapy from a CHW for 6 months
Study: NCT00502281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: highly purified urinary FSH
Study: NCT02910583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: venetoclax
Description: venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
Study: NCT01737619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Solution
Description: Given via superficial and deep cervical injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02910583

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules to match ibrutinib administered orally once daily
Study: NCT01737619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Undergo lymph node mapping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo full lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT00502281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: highly purified urinary FSH

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: timed intercourses, intrauterine insemination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: timed intercourses, intrauterine insemination
Study: NCT04011384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economic intervention of online purchasing at a food pantry
Description: This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
Study: NCT04361747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nursing counseling
Description: The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
Study: NCT01060566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
Study: NCT01169519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil by injection
Description: Sildenafil 0.125mg/kg injection over 20min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil by injection
Description: Sildenafil 0.25mg/kg injection over 20min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil by injection
Description: Sildenafil 0.35mg/kg by injection over 20min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil by injection
Description: Sildenafil 0.45mg/kg by injection over 20min
Study: NCT00852475

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MUFA MOVE! (Monounsaturated fatty enriched diet)
Description: MUFA MOVE!diet and exercise program

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PUFA MOVE! (Polyunsaturated fatty acid enriched diet)
Description: PUFA MOVE! diet and exercise program
Study: NCT00594932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant). During the fourth month mycophenolate mofetil will be given in ascending doses to 3 gms/day (or less if tolerance issues arise) and continues until the end of the study at 6 months.
Study: NCT04478747

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVM
Description: Transvaginal mesh operation using BSC mesh (A.M.I., Feldkirch, Austria)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposacropexy
Description: Colposacropexy using EndoGYNious mesh (A.M.I., Feldkirch, Austria)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposacropexy
Description: Colposacropexy using EndoGYNious mesh (A.M.I., Feldkirch, Austria)
Study: NCT00480441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: 10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BRENDA therapy
Description: weekly therapy sessions for 6 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BRENDA therapy
Description: weekly therapy sessions for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules daily for 2 weeks followed by a 1 week taper
Study: NCT03908099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit-For-Fertility program
Description: The Fit-for-Fertility Program aims at implementing progressive and sustainable lifestyle changes. Participants will attend individual sessions with a dietitian and a kinesiologist every 6 weeks for the first 6 months, then every 8 weeks for the 6 following months, and then every 12 weeks until end of the study. Follow-up by telephone/e-mail will be offered between in-person meetings. These professionals will be trained in motivational counselling skills. Participants will also benefit from weekly group sessions divided into 2 parts: 1) Workshops covering 8 different topics (45 minutes) addressing healthy lifestyle and 2) Supervised classes of physical activity where one of 8 different types of exercise (45 minutes) will be practiced. Women will be required to attend all 8 different sessions within the first 6 months. Pregnant women will be met to set new lifestyle objectives specific to pregnancy, including optimal gestational weight gain based on the Institute of Medicine guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months. The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
Study: NCT02974309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Routine
Description: All youth in this condition are asked to follow the routines set by their clinical care team.
Study: NCT04482478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extract of Dolichos lablab Linne (EDL)
Description: Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo: consumed in the same way as the investigational product
Study: NCT01706692

Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: all dosages, frequencies and durations prescribed

Intervention type: BIOLOGICAL
Intervention: Etanercept
Description: all dosages, frequencies and durations prescribed

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: all dosages, frequencies and durations prescribed

Intervention type: BIOLOGICAL
Intervention: Ustekinumab
Description: all dosages, frequencies and durations prescribed

Intervention type: DRUG
Intervention: Cyclosporine A
Description: all dosages, frequencies and durations prescribed

Intervention type: DRUG
Intervention: Fumaric acids
Description: all dosages, frequencies and durations prescribed

Intervention type: DRUG
Intervention: Methotrexate
Description: all dosages, frequencies and durations prescribed

Intervention type: DRUG
Intervention: Other anti-psoriatic systemic treatments
Description: all dosages, frequencies and durations prescribed
Study: NCT02978560

Intervention type: DIAGNOSTIC_TEST
Intervention: fluorescence-mediated photoplethysmography
Description: Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.

Intervention type: DIAGNOSTIC_TEST
Intervention: fluorescence-mediated photoplethysmography
Description: Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.
Study: NCT02696993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02785601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride prolonged-release tablets
Description: strength 75mg, 150 mg. Oral administration with 200ml water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride prolonged-release tablets
Description: strength 75mg, 150 mg. Oral administration with 200ml water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride prolonged-release tablets
Description: strength 75mg, 150 mg. Oral administration with 200ml water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride prolonged-release tablets
Description: strength 75mg, 150 mg. Oral administration with 200ml water
Study: NCT02696993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study: NCT01687270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
Study: NCT04808869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
Study: NCT05930899

Intervention type: OTHER
Intervention: Genetics
Description: TOmAS is a biobank and all patients will be genotyped

Intervention type: OTHER
Intervention: Genetics
Description: TOmAS is a biobank and all patients will be genotyped
Study: NCT03358147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI 7.2 μg
Description: GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo taken as 2 inhalations BID
Study: NCT02179918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05082566
Description: Starting dose of 0.45 mg/kg q3wks IV, dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 2 mg/kg q3wks, IV
Study: NCT01385176

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implant of investigational device system
Description: Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.
Study: NCT01615627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HypotonicTreprostinil Solution
Description: Hypotonic Treprostinil Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eutonic Treprostinil Solution
Description: Eutonic Treprostinil Solution